Hodgkin's Lymphoma Clinical Trials

Double Cord Versus Haploidentical (BMT CTN 1101)

Hematopoietic cell transplants (HCT)are one treatment option for people with leukemia or lymphoma. Family members,unrelated donors or banked umbilical cordblood units with similar tissue type can b...

Diagnosis: Leukemia/MDS, Hodgkin's Lymphoma

Phase: 3

Protocol Number: 12-188

Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma

This research is being done in order to improve treatment outcomes in patients diagnosed with bulky, early stage Hodgkin lymphoma and to reduce the side effects that are associated with use of radi...

Diagnosis: Hodgkin's Lymphoma

Phase: 2

Protocol Number: 10-327

A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

The purpose of this study is to assess the safety profile and antitumor activity of brentuximab vedotin administered in combination with nivolumab in patients with relapsed or refractory Hodgkin ly...

Diagnosis: Hodgkin's Lymphoma

Phase: 1 / 2

Protocol Number: 16-090

Safety Study of Nivolumab and Ipilimumab in Hematologic Malignancy

The purpose of this study is to determine the side effects of treatment with Nivolumab alone and in combination with Ipilimumab in subjects with hematological malignancies and the dose that should ...

Diagnosis: Hodgkin's Lymphoma, Lymphoma

Phase: 1

Protocol Number: 12-317

Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

The purpose of this study is to establish a dosing regimen for the combination therapy of AFM13 and pembrolizumab (MK-3475) in patients with relapsed or refractory (R/R) Hodgkin Lymphoma (HL) and t...

Diagnosis: Hodgkin's Lymphoma

Phase:

Protocol Number: 16-416

A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,

The purpose of this study is to determine whether an investigational immuno-therapy combination, nivolumab with Brentuximab vedotin compared to Brentuximab vedotin alone is safe and effective in th...

Diagnosis: Hodgkin's Lymphoma

Phase:

Protocol Number: 17-282